Medivir Notes that Partner Tibotec Announced Week 24 Interim Results from Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD
Huddinge, Sweden - Medivir AB (OMX:MVIR), the research-based speciality pharmaceutical company focused on the development of high-value treatments for infectious diseases, notes that its development partner, Tibotec Pharmaceuticals, has announced the results of a Week-24 planned interim analysis of the Phase 2 response-guided PILLAR study for TMC435, Medivir’s key pipeline asset, a hepatitis C protease inhibitor dosed once-daily. The study was conducted in treatment-naïve patients with chronic genotype 1 Hepatitis C virus (HCV) and is part of a late-breaker oral presentation at the 61st